What is semaglutide?
Semaglutide is a GLP-1 receptor agonist. Ozempic and Wegovy are approved products with their own indications, presentations and instructions. This guide focuses on weight management; sharing an ingredient does not make their doses or formulations interchangeable. Wegovy labeling.
How it works in the body
Semaglutide acts on appetite-regulating pathways and can reduce calorie intake. It also delays gastric emptying and changes insulin and glucagon secretion in a glucose-dependent manner. Changes in hunger and thoughts about food vary between people. Wegovy labeling.
Efficacy: how much weight people lose
In STEP 1, 1,961 adults without diabetes received semaglutide 2.4 mg weekly or placebo alongside lifestyle intervention. Average weight loss at 68 weeks was 14.9% versus 2.4%. Participants had BMI ≥30, or ≥27 with a weight-related condition. These trial results do not predict your response or establish efficacy for a compounded preparation. STEP 1.
Dosing and titration
The usual Wegovy injection starting schedule increases through 0.25 mg, 0.5 mg, 1 mg and 1.7 mg weekly, with four weeks at each step; maintenance depends on the indication and tolerability. This label overview is not a dosing plan for your compounded preparation. Follow your prescription and pharmacy instructions; do not convert milligrams to syringe units without confirming the concentration. Wegovy labeling.
Side effects
Nausea, diarrhea, vomiting and constipation are common. Severity and duration vary. Contact your clinician if you cannot keep fluids down or symptoms persist; seek urgent care for severe persistent abdominal pain or signs of a serious allergic reaction. Wegovy labeling.
Who is a candidate?
For adults, weight-management eligibility includes obesity or overweight with a weight-related condition. Meeting a BMI threshold does not by itself establish that treatment is appropriate. Wegovy labeling.
Wegovy and Zepbound labeling contraindicates use with a personal or family history of medullary thyroid carcinoma (MTC), MEN 2, or hypersensitivity to the product. Other conditions call for specific precautions rather than a blanket contraindication.
- Pregnancy: weight loss offers no benefit during pregnancy. Discuss pregnancy plans; semaglutide should be stopped at least two months before a planned pregnancy. Breastfeeding decisions depend on the product and individual circumstances.
- Digestive symptoms, pancreas and gallbladder: disclose pancreatitis, gallstones and gastroparesis. These products are not recommended with severe gastroparesis. Severe persistent abdominal pain needs urgent medical assessment.
- Kidneys, glucose and eyes: vomiting or diarrhea can cause dehydration and kidney injury. Insulin and sulfonylureas increase hypoglycemia risk. Diabetic retinopathy may need monitoring.
- Other treatment: do not combine GLP-1 medicines on your own. Tell clinicians about planned anesthesia. With tirzepatide, discuss additional or non-oral contraception for four weeks after starting and after each dose increase.
A compounded preparation also requires assessment of its ingredients, concentration and preparation-specific risks. Approved-product warnings do not establish equivalent safety. Wegovy labeling.
Read the product-specific tirzepatide precautions as well. Zepbound labeling.
Compounded vs. brand semaglutide
A compounded preparation is not FDA-approved or established as equivalent to Ozempic or Wegovy. FDA recommends considering it only when an approved medicine cannot meet a patient’s medical needs. FDA.
Semaglutide sodium and semaglutide acetate are salt forms different from the ingredient in approved medicines. FDA states it is unaware of a lawful basis for their use in compounding. Verify the ingredient and instructions with the pharmacy; this guide does not verify a particular batch. FDA.
An individual prescription alone does not satisfy every legal condition. Restrictions on copies of commercially available medicines continue after the shortage. FDA.
Compare the full cost.
These are REMEVi compounded program prices. Brand prices depend on the prescribed product, coverage and savings eligibility. Four weeks means 28 days, not a calendar month.
Semaglutide
Prescribed medication if approved, clinician evaluation and follow-up, shipping and bilingual support are included. Lab tests required by your clinician for the GLP-1 program are included in your plan price.
The monthly plan is billed every 4 weeks. The 12-week and 24-week plans are prepaid for the full term, with the total charge shown before you choose. Review the renewal terms at checkout and in your patient portal. You can cancel future renewals without a cancellation fee. Prepaid terms are paid in advance; refund eligibility is governed by the Cancellation & Refund Policy.
All plans & included care · Semaglutide cost breakdown · Refund terms
Make your next conversation useful.
Keep a list of your medicines, symptoms and questions. Treatment is an ongoing clinical decision, with dose changes guided by the prescriber. A study average is not a personal target or a deadline.
- Why is this exact medicine appropriate for my history and goals?
- If it is compounded, why can an approved medicine not meet my medical needs?
- What is my dose, concentration, syringe and schedule? What happens after a missed dose?
- Which symptoms need a message, a same-day call or emergency care?
- When will we review progress, nutrition, strength and tolerability?
- Who prescribes and dispenses my medication, and how do I reach them?
Common questions.
What should I know before starting?
Confirm which product is prescribed, why it is appropriate for you and how to use it. Discuss your health history, other medicines and pregnancy plans, and agree on follow-up with your clinician.
Is a brand product the same as a compounded preparation?
Compounded preparations are not FDA-approved or established as equivalent to brand products. FDA recommends considering them only when an approved medicine cannot meet a patient’s medical needs. Evaluation and prescribing are individual.
When will I see results?
There is no guaranteed date or amount of weight loss. Response depends on the product, tolerated dose and other factors. Trials assess averages over many months; they do not predict your individual result.
Which side effects need attention?
Nausea, vomiting, diarrhea or constipation can occur, particularly during dose increases. Severity and duration vary. Seek medical care for severe persistent abdominal pain, inability to keep fluids down or symptoms of a serious allergic reaction. Do not change your dose on your own.
How should I compare costs?
REMEVi semaglutide: From $159 per 4 weeks with the 24-week plan: $954 paid upfront. Or $199 every 4 weeks without a long-term prepayment. REMEVi tirzepatide: From $225 per 4 weeks with the 24-week plan: $1,350 paid upfront. Or $269 every 4 weeks without a long-term prepayment. Four weeks is not a calendar month. Brand products may have different costs depending on insurance, presentation and savings eligibility.
Sources & review history.
- Wegovy: prescribing information
- STEP 1: semaglutide trial (NEJM, 2021)
- FDA: unapproved GLP-1 products and patient safety
- NIDDK: prescription treatment for overweight and obesity
- FDA: post-shortage compounding requirements (April 2026 update)
- Zepbound: prescribing information
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·
Medical team. Editorial update: September 17, 2026. Educational information; not individual medical advice. Editorial policy.